{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:21:56Z","timestamp":1792077716421,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1K23DK122126"],"award-info":[{"award-number":["1K23DK122126"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["1R03DK140420"],"award-info":[{"award-number":["1R03DK140420"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.diabres.2025.112982","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:13:36Z","timestamp":1761959616000},"page":"112982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6391","authenticated-orcid":false,"given":"Alexander T.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Y.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukgu M.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-9482","authenticated-orcid":false,"given":"Tze-Woei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.diabres.2025.112982_b0005","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112982_b0010","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the american heart association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.diabres.2025.112982_b0015","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14552","article-title":"Predicting major adverse limb events in individuals with type 2 diabetes: insights from the EXSCEL trial","volume":"38","author":"Weissler","year":"2021","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1526602817705135","article-title":"Major limb outcomes following lower extremity endovascular revascularization in patients with and without diabetes mellitus","volume":"24","author":"Shammas","year":"2017","journal-title":"J Endovasc Ther"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/ATVBAHA.119.312863","article-title":"Impaired regeneration contributes to poor outcomes in diabetic peripheral artery disease","volume":"40","author":"Fadini","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/dc24-1644","article-title":"Trends in peripheral artery disease, lower-extremity revascularization, and lower-extremity amputation in incident type 2 diabetes: a Danish population-based cohort study","volume":"48","author":"Gyldenkerne","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.112982_b0035","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/diacare.24.8.1433","article-title":"Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome","volume":"24","author":"Jude","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112982_b0040","first-page":"0702","article-title":"Forecasting the global burden of peripheral artery disease from 2021 to 2050: a population-based study","volume":"8","author":"Deng","year":"2021","journal-title":"Research (Wash D C)"},{"key":"10.1016\/j.diabres.2025.112982_b0045","doi-asserted-by":"crossref","unstructured":"GBD 2019 Peripheral Artery Disease Collaborators. Global burden of peripheral artery disease and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Glob Health. 2023;11(10):e1553-e1565. doi:10.1016\/S2214-109X(23)00355-8.","DOI":"10.1016\/S2214-109X(23)00355-8"},{"issue":"21","key":"10.1016\/j.diabres.2025.112982_b0050","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.3390\/jcm10215033","article-title":"Diabetes mellitus and its impact on patient-profile and in-hospital outcomes in peripheral artery disease","volume":"10","author":"Keller","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12933-024-02226-x","article-title":"Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: an observational, register-based cohort study","volume":"23","author":"Avdic","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112982_b0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/clc.22657","article-title":"Impact of diabetes on mortality in peripheral artery disease: a meta-analysis","volume":"40","author":"Vrsalovic","year":"2017","journal-title":"Clin Cardiol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112982_b0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1358863X16643603","article-title":"Mortality rates at 10 years are higher in diabetic than in non-diabetic patients with chronic lower extremity peripheral arterial disease","volume":"21","author":"Mueller","year":"2016","journal-title":"Vasc Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1358863X08089277","article-title":"National health care costs of peripheral arterial disease in the Medicare population","volume":"13","author":"Hirsch","year":"2008","journal-title":"Vasc Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1053\/j.semvascsurg.2023.01.007","article-title":"Disparities in limb preservation and associated socioeconomic burden among patients with diabetes and\/or peripheral artery disease in the United States","volume":"36","author":"McDermott","year":"2023","journal-title":"Semin Vasc Surg"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12933-024-02325-9","article-title":"Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review","volume":"23","author":"Mah\u00e9","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112982_b0085","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.diabres.2025.112982_b0090","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.diabres.2025.112982_b0095","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2025.112982_b0100","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.diabres.2025.112982_b0105","doi-asserted-by":"crossref","unstructured":"Hong AT, Luu IY, Lin F, et al. Differential Effect of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Lower-Extremity Amputation Outcomes in Type 2 Diabetes: A Nationwide Retrospective Cohort Study. Diabetes Care. Published online June 25, 2025:dc250292. doi:10.2337\/dc25-0292.","DOI":"10.2337\/dc25-0292"},{"key":"10.1016\/j.diabres.2025.112982_b0110","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.diabres.2025.112982_b0115","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"D\u2019Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.amjmed.2016.10.016","article-title":"Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients","volume":"130","author":"Chang","year":"2017","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.diabres.2025.112982_b0130","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.diabres.2025.112982_b0135","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7624","key":"10.1016\/j.diabres.2025.112982_b0140","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0145","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0801","article-title":"Foot and ankle care by podiatrists and amputations in patients with diabetes and kidney failure","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.diabres.2025.112982_b0150","doi-asserted-by":"crossref","DOI":"10.2196\/18542","article-title":"Model-based algorithms for detecting peripheral artery disease using administrative data from an electronic health record data system: algorithm development study","volume":"8","author":"Weissler","year":"2020","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.diabres.2025.112982_b0155","unstructured":"Cronenwett JL, Birkmeyer JD. Table 6. CPT Codes. October 2000. Accessed October 2, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK588524\/table\/ta6\/."},{"issue":"8","key":"10.1016\/j.diabres.2025.112982_b0160","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.diabres.2025.112982_b0165","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/dom.14671","article-title":"Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial","volume":"24","author":"Barraclough","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.diabres.2025.112982_b0170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.diabres.2025.112982_b0175","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008018","article-title":"Clinical outcomes in patients with type 2 diabetes mellitus and peripheral artery disease: results from the EXSCEL trial","volume":"12","author":"Badjatiya","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"25","key":"10.1016\/j.diabres.2025.112982_b0180","first-page":"01112","article-title":"Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease","volume":"S0741\u20135214","author":"Go","year":"2025","journal-title":"J Vasc Surg Published online June 6"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112982_b0190","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13098-023-00982-6","article-title":"Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"15","author":"Lee","year":"2023","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"10.1016\/j.diabres.2025.112982_b0195","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3390\/ijms25031854","article-title":"Impact of glucagon-like peptide 1 receptor agonists on biochemical markers of the initiation of atherosclerotic process","volume":"25","author":"Hachu\u0142a","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.diabres.2025.112982_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113517","article-title":"Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists","volume":"153","author":"Wu","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabres.2025.112982_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2020.111005","article-title":"Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1\/2\/NF-\u03baB signalling pathway","volume":"518","author":"Fan","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112982_b0210","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.124.320714","article-title":"Novel angiogenesis role of GLP-1(32-36) to rescue diabetic ischemic lower limbs via GLP-1R-dependent glycolysis in mice","volume":"44","author":"Zhang","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2025.112982_b0215","first-page":"9","article-title":"GLP-1 improves adipocyte insulin sensitivity following induction of endoplasmic reticulum stress","author":"Jiang","year":"2018","journal-title":"Front Pharmacol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:56:54Z","timestamp":1781067414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S0168822725009969"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112982","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112982"}}